Low-dose arsenic-mediated metabolic shift is associated with activation of polo-like kinase 1 (Plk1)

Cell Cycle

Volumn 14, Issue 19, 2015, Pages 3030-3039

  Li, Zhiguo ^a   Lu, Ying ^a,b   Ahmad, Nihal ^c   Strebhardt, Klaus ^d   Liu, Xiaoqi ^a,e  

^a PURDUE UNIVERSITY   (United States)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e Purdue University   (United States)

Author keywords

Low dose arsenic; Metabolic shift; NF B; PI3K AKT mTOR pathway; Plk1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARSENIC TRIOXIDE; ARSENITE SODIUM; CARBON DIOXIDE; DOXYCYCLINE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; RAPAMYCIN; ARSENIC; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBON DIOXIDE EVOLUTION; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE HOMEOSTASIS; GLUCOSE INTAKE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC PARAMETERS; METABOLIC SWITCH; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; ANIMAL; CELL CYCLE; CELL LINE; DRUG EFFECTS; GENETICS; GENOTYPE; IMMUNOPRECIPITATION; METABOLISM;

ANIMALS; ARSENIC; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; ENERGY METABOLISM; GENOTYPE; GLYCOLYSIS; HUMANS; IMMUNOPRECIPITATION; MICE; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84944909448     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1080397     Document Type: Article

References (37)

1. Celik I, Gallicchio L, Boyd K, Lam TK, Matanoski G, Tao X, Shiels M, Hammond E, Chen L, Robinson KA, et al. Arsenic in drinking water and lung cancer: a systematic review. Environ Res 2008; 108:48-55; PMID:18511031; http://dx.doi.org/10.1016/j.envres.2008.04.001
2. Surdu S. Non-melanoma skin cancer: occupational risk from UV light and arsenic exposure. Rev Environ Health 2014; 29:255-64; PMID:25222586; http://dx.doi.org/10.1515/reveh-2014-0040
3. Tsuji JS, Alexander DD, Perez V, Mink PJ. Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses. Toxicology 2014; 317:17-30; PMID:24462659; http://dx.doi.org/10.1016/j.tox.2014.01.004
4. Wang W, Cheng S, Zhang D. Association of inorganic arsenic exposure with liver cancer mortality: A metaanalysis. Environ Res 2014; 135:120-5; PMID:25262084; http://dx.doi.org/10.1016/j.envres.2014.08.034
5. Chen YJ, Lai KC, Kuo HH, Chow LP, Yih LH, Lee TC. HSP70 colocalizes with PLK1 at the centrosome and disturbs spindle dynamics in cells arrested in mitosis by arsenic trioxide. Arch Toxicol 2014; 88:1711-23; PMID:24623308; http://dx.doi.org/10.1007/s00204-014-1222-x
6. Ganapathy S, Xiao S, Seo SJ, Lall R, Yang M, Xu T, Su H, Shadfan M, Ha CS, Yuan ZM. Low-dose arsenic induces chemotherapy protection via p53/NF-kappaBmediated metabolic regulation. Oncogene 2014; 33:1359-66; PMID:23524579; http://dx.doi.org/10.1038/onc.2013.81
7. Huang Y, Zhang J, McHenry KT, Kim MM, Zeng W, Lopez-Pajares V, Dibble CC, Mizgerd JP, Yuan ZM. Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res 2008; 68:9131-6; PMID:19010883; http://dx.doi.org/10.1158/0008-5472.CAN-08-3025
8. Ganapathy S, Xiao S, Yang M, Qi M, Choi DE, Ha CS, Little JB, Yuan ZM. A low-dose arsenic-induced p53 protein-mediated metabolic mechanism of radiotherapy protection. J Biol Chem 2014; 289:5340-7; PMID:24391088; http://dx.doi.org/10.1074/jbc.M113.531020
9. Li L, Lu Y, Stemmer PM, Chen F. Filamin A phosphorylation by Akt promotes cell migration in response to arsenic. Oncotarget 2015; 6:12009-19; PMID:25944616
10. Chen YJ, Lin YP, Chow LP, Lee TC. Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide- induced mitotically arrested cells. Proteomics 2011; 11:4331-45; PMID:21887822; http://dx.doi.org/10.1002/pmic.201100329
11. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
12. Liu XS, Song B, Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell 2010; 1:999-1010; PMID:21153517; http://dx.doi.org/10.1007/s13238-010-0131-x
13. Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, Ratliff T, Konieczny SF, Ahmad N, Kuang S, et al. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol 2014; 34:3642-61; PMID:25047839; http://dx.doi.org/10.1128/MCB.00814-14
14. Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration- resistant prostate cancer. Cancer Res 2014; 74:6635-47; PMID:25252916; http://dx.doi.org/10.1158/0008-5472.CAN-14-1916
15. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 1999; 100:1330-7; PMID:10491379; http://dx.doi.org/10.1161/01.CIR.100.12.1330
16. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17:304-15; PMID:17291761; http://dx.doi.org/10.1016/j.cub.2006.12.046
17. Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2011; 2:395; PMID:21772266; http://dx.doi.org/10.1038/ncomms1395
18. Choi BH, Pagano M, Dai W. Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle. J Biol Chem 2014; 289:14066-74; PMID:24706748; http://dx.doi.org/10.1074/jbc.M114.558155
19. Duan Q, Komissarova E, Dai W. Arsenic trioxide suppresses paclitaxel-induced mitotic arrest. Cell Prolif 2009; 42:404-11; PMID:19397590; http://dx.doi.org/10.1111/j.1365-2184.2009.00606.x
20. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide- induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003; 17:1333-7; PMID:12835721; http://dx.doi.org/10.1038/sj.leu.2402983
21. Winski SL, Carter DE. Arsenate toxicity in human erythrocytes: characterization of morphologic changes and determination of the mechanism of damage. J Toxicol Environ Health A 1998; 53:345-55; PMID:9515938; http://dx.doi.org/10.1080/009841098159213
22. Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle 2013; 12:1473-4; PMID:23624839; http://dx.doi.org/10.4161/cc.24747
23. Lin S, Cullen WR, Thomas DJ. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 1999; 12:924-30; PMID:10525267; http://dx.doi.org/10.1021/tx9900775
24. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997; 386:263-77; PMID:9219564; http://dx.doi.org/10.1016/S1383-5742(97)00008-2
25. Hu Y, Su L, Snow ET. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res 1998; 408:203-18; PMID:9806419; http://dx.doi.org/10.1016/S0921-8777(98)00035-4
26. Dong Z. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect 2002; 110 Suppl 5:757-9; PMID:12426127; http://dx.doi.org/10.1289/ehp.02110s5757
27. Shi Q, Sutariya V, Bishayee A, Bhatia D. Sequential activation of Elk-1/Egr-1/GADD45alpha by arsenic. Oncotarget 2014; 5:3862-70; PMID:25004251
28. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003; 100:5789-94; PMID:12732729; http://dx.doi.org/10.1073/pnas.1031523100
29. Liu XS, Li H, Song B, Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep 2010; 11:626-32; PMID:20577264; http://dx.doi.org/10.1038/embor.2010.90
30. Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, Liu X. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 2009; 284:18588-92; PMID:19473992; http://dx.doi.org/10.1074/jbc.C109.001560
31. Lin DC, Zhang Y, Pan QJ, Yang H, Shi ZZ, Xie ZH, Wang BS, Hao JJ, Zhang TT, Xu X, et al. PLK1 Is transcriptionally activated by NF-kappaB during cell detachment and enhances anoikis resistance through inhibiting b-catenin degradation in esophageal squamous cell carcinoma. Clin Cancer Res 2011; 17:4285-95; PMID:21610149; http://dx.doi.org/10.1158/1078-0432.CCR-10-3236
32. Song B, Liu XS, Davis K, Liu X. Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol 2011; 31:4844-56; PMID:21947279; http://dx.doi.org/10.1128/MCB.06110-11
33. Wu ZQ, Liu X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A 2008; 105:1919-24; PMID:18250300; http://dx.doi.org/10.1073/pnas.0712063105
34. Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2013; 12:58-68; PMID:23188630; http://dx.doi.org/10.1158/1535-7163.MCT-12-0632
35. Li H, Liu XS, Yang X, Wang Y, Turner JR, Liu X. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. Embo J 2010; 29:2953-65; PMID:20664522; http://dx.doi.org/10.1038/emboj.2010.174
36. Li H, Liu XS, Yang X, Song B, Wang Y, Liu X. Pololike kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A 2010; 107:14633-8; PMID:20679239; http://dx.doi.org/10.1073/pnas.1006615107
37. Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 2013; 73:1352-63; PMID:23661607; http://dx.doi.org/10.1002/pros.22683